People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Centese, Inc. | — | Other Health Care | Series B | $15.6M | $2.7M | 2023 |
| Esculon, Inc. | — | Biotechnology | Seed | $2.9M | $129.9M | 2017 |
| Respirix, Inc. | — | Other Health Care | Seed | $1.3M | $32.2M | 2018 |
Evan Luxon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Evan Luxon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Burnett | 2 | 11 |
| Alan Chesler | 2 | 5 |
| Deepak Gangahar | 2 | 2 |
| Carter Meyer | 1 | 14 |
| Radu Cautis | 1 | 2 |
| Eric Kriegstein | 1 | 2 |
| Dan Burnett | 1 | 2 |
| Danial Burnett | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.